 Vijaya Knight
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 4 | 2023 | 68 | 2.160 |
Why?
| | Flow Cytometry | 5 | 2025 | 1165 | 1.850 |
Why?
| | Antibodies, Viral | 8 | 2022 | 674 | 1.540 |
Why?
| | Antibodies, Neutralizing | 3 | 2021 | 340 | 1.220 |
Why?
| | Cytokines | 4 | 2022 | 2069 | 1.140 |
Why?
| | Autoantibodies | 4 | 2022 | 1509 | 1.090 |
Why?
| | Immunoglobulin E | 4 | 2026 | 315 | 0.980 |
Why?
| | Laboratories | 3 | 2021 | 110 | 0.940 |
Why?
| | Allergy and Immunology | 2 | 2026 | 43 | 0.870 |
Why?
| | Immunoglobulin Class Switching | 1 | 2025 | 21 | 0.870 |
Why?
| | Immunoglobulin G | 6 | 2025 | 892 | 0.870 |
Why?
| | B-Lymphocytes | 3 | 2025 | 872 | 0.850 |
Why?
| | Immune System Diseases | 1 | 2025 | 37 | 0.850 |
Why?
| | Germinal Center | 1 | 2025 | 64 | 0.840 |
Why?
| | Antigens, Viral | 3 | 2021 | 182 | 0.830 |
Why?
| | Laboratory Proficiency Testing | 2 | 2021 | 9 | 0.820 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2024 | 88 | 0.800 |
Why?
| | Immunophenotyping | 1 | 2024 | 322 | 0.750 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 481 | 0.740 |
Why?
| | Immunoassay | 3 | 2021 | 109 | 0.730 |
Why?
| | Allergens | 3 | 2026 | 386 | 0.670 |
Why?
| | Convalescence | 1 | 2021 | 19 | 0.660 |
Why?
| | Pathology, Clinical | 1 | 2020 | 29 | 0.640 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 33 | 0.630 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.600 |
Why?
| | Blood Donors | 1 | 2021 | 144 | 0.580 |
Why?
| | Interferon-gamma | 3 | 2022 | 784 | 0.570 |
Why?
| | Coronavirus Infections | 2 | 2021 | 384 | 0.550 |
Why?
| | Antibody Specificity | 1 | 2018 | 179 | 0.540 |
Why?
| | Spike Glycoprotein, Coronavirus | 5 | 2022 | 129 | 0.540 |
Why?
| | Societies, Medical | 2 | 2026 | 900 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.510 |
Why?
| | Immunotherapy | 1 | 2021 | 668 | 0.460 |
Why?
| | Hypersensitivity | 1 | 2018 | 254 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.440 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2014 | 339 | 0.440 |
Why?
| | Sensitivity and Specificity | 5 | 2021 | 2000 | 0.430 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 95 | 0.390 |
Why?
| | Humans | 41 | 2026 | 145783 | 0.380 |
Why?
| | Food Hypersensitivity | 1 | 2015 | 164 | 0.380 |
Why?
| | Nickel | 1 | 2013 | 62 | 0.370 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2013 | 73 | 0.360 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2022 | 133 | 0.350 |
Why?
| | Leukocytes, Mononuclear | 2 | 2022 | 574 | 0.350 |
Why?
| | Immunologic Factors | 1 | 2013 | 260 | 0.340 |
Why?
| | Serologic Tests | 2 | 2021 | 54 | 0.320 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3418 | 0.320 |
Why?
| | Common Variable Immunodeficiency | 2 | 2021 | 26 | 0.280 |
Why?
| | Pandemics | 3 | 2021 | 1711 | 0.270 |
Why?
| | Egg Proteins | 1 | 2026 | 20 | 0.230 |
Why?
| | Eggs | 1 | 2026 | 25 | 0.230 |
Why?
| | Egg Hypersensitivity | 1 | 2026 | 28 | 0.230 |
Why?
| | Lupus Nephritis | 1 | 2025 | 67 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 108 | 0.220 |
Why?
| | Phenotype | 3 | 2024 | 3170 | 0.210 |
Why?
| | CD56 Antigen | 1 | 2024 | 34 | 0.210 |
Why?
| | Leukocyte Common Antigens | 1 | 2024 | 87 | 0.200 |
Why?
| | Lymphocytes | 2 | 2024 | 376 | 0.200 |
Why?
| | Immunization, Passive | 2 | 2022 | 90 | 0.200 |
Why?
| | Education, Medical, Undergraduate | 1 | 2026 | 208 | 0.200 |
Why?
| | Immunologic Techniques | 1 | 2023 | 38 | 0.200 |
Why?
| | Immunoglobulin A | 1 | 2025 | 214 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 849 | 0.190 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2024 | 93 | 0.190 |
Why?
| | Immunologic Memory | 1 | 2025 | 368 | 0.180 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2021 | 17 | 0.180 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2021 | 37 | 0.170 |
Why?
| | Cross Reactions | 1 | 2021 | 130 | 0.170 |
Why?
| | Monocytes | 1 | 2024 | 539 | 0.170 |
Why?
| | Male | 12 | 2025 | 73010 | 0.170 |
Why?
| | Transplantation Immunology | 1 | 2021 | 29 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 101 | 0.160 |
Why?
| | Precision Medicine | 1 | 2025 | 461 | 0.160 |
Why?
| | Vero Cells | 1 | 2021 | 83 | 0.160 |
Why?
| | Histocompatibility Testing | 1 | 2021 | 123 | 0.160 |
Why?
| | Microarray Analysis | 1 | 2021 | 117 | 0.160 |
Why?
| | Emergency Responders | 1 | 2021 | 37 | 0.160 |
Why?
| | Hexosephosphates | 1 | 2020 | 2 | 0.160 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2020 | 10 | 0.160 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 28 | 0.160 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 161 | 0.160 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2020 | 10 | 0.160 |
Why?
| | Group Processes | 1 | 2021 | 63 | 0.160 |
Why?
| | Phosphorylation | 1 | 2025 | 1708 | 0.160 |
Why?
| | Adult | 8 | 2025 | 40881 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 129 | 0.160 |
Why?
| | RNA, Viral | 2 | 2024 | 693 | 0.160 |
Why?
| | Coronavirus | 1 | 2021 | 47 | 0.160 |
Why?
| | Glucosides | 1 | 2020 | 56 | 0.160 |
Why?
| | Specimen Handling | 1 | 2022 | 183 | 0.160 |
Why?
| | Female | 12 | 2025 | 79045 | 0.150 |
Why?
| | Benzhydryl Compounds | 1 | 2020 | 81 | 0.150 |
Why?
| | Neutropenia | 1 | 2020 | 154 | 0.150 |
Why?
| | Interleukin-13 | 1 | 2020 | 146 | 0.150 |
Why?
| | Congresses as Topic | 1 | 2021 | 224 | 0.150 |
Why?
| | Th2 Cells | 1 | 2020 | 175 | 0.150 |
Why?
| | Virtual Reality | 1 | 2021 | 82 | 0.150 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2123 | 0.150 |
Why?
| | Curriculum | 1 | 2026 | 1074 | 0.140 |
Why?
| | Phenylalanine Ammonia-Lyase | 1 | 2018 | 1 | 0.140 |
Why?
| | Phenylketonurias | 1 | 2018 | 15 | 0.140 |
Why?
| | Plasma | 1 | 2020 | 223 | 0.140 |
Why?
| | Antigen-Antibody Complex | 1 | 2018 | 69 | 0.140 |
Why?
| | Immunomodulation | 1 | 2019 | 99 | 0.140 |
Why?
| | Peanut Hypersensitivity | 1 | 2020 | 143 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 489 | 0.140 |
Why?
| | Skin Tests | 1 | 2018 | 94 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2020 | 337 | 0.140 |
Why?
| | Gamma Rays | 1 | 2018 | 57 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 361 | 0.130 |
Why?
| | Transfusion Reaction | 1 | 2018 | 61 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 469 | 0.130 |
Why?
| | Animals | 5 | 2025 | 38101 | 0.130 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 90 | 0.130 |
Why?
| | Lung Diseases | 2 | 2014 | 782 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2968 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 602 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 397 | 0.120 |
Why?
| | Child, Preschool | 4 | 2026 | 11868 | 0.120 |
Why?
| | Epoxy Resins | 1 | 2015 | 3 | 0.120 |
Why?
| | Genetic Testing | 1 | 2019 | 483 | 0.120 |
Why?
| | Listeriosis | 1 | 2016 | 63 | 0.110 |
Why?
| | B-Cell Activation Factor Receptor | 1 | 2015 | 12 | 0.110 |
Why?
| | Aged | 4 | 2025 | 26217 | 0.110 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 279 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1368 | 0.110 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 385 | 0.110 |
Why?
| | Spirometry | 1 | 2015 | 233 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2024 | 6465 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1127 | 0.110 |
Why?
| | Immune System | 1 | 2015 | 180 | 0.100 |
Why?
| | Retrospective Studies | 2 | 2025 | 17330 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2016 | 311 | 0.100 |
Why?
| | Occupational Diseases | 1 | 2015 | 165 | 0.100 |
Why?
| | Hematologic Tests | 1 | 2013 | 22 | 0.100 |
Why?
| | Infant | 2 | 2026 | 10091 | 0.100 |
Why?
| | Patch Tests | 1 | 2013 | 60 | 0.090 |
Why?
| | Algorithms | 1 | 2021 | 1851 | 0.090 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 189 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2018 | 2514 | 0.090 |
Why?
| | Pneumonia | 2 | 2015 | 636 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 210 | 0.090 |
Why?
| | Mycobacterium avium Complex | 1 | 2013 | 87 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 171 | 0.090 |
Why?
| | Mutation | 2 | 2022 | 4090 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1296 | 0.090 |
Why?
| | Signal Transduction | 1 | 2025 | 5224 | 0.080 |
Why?
| | Middle Aged | 4 | 2025 | 36309 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2013 | 474 | 0.080 |
Why?
| | Lymphocyte Activation | 3 | 2020 | 1133 | 0.080 |
Why?
| | Adolescent | 3 | 2025 | 22577 | 0.080 |
Why?
| | Time Factors | 1 | 2021 | 7134 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2884 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1998 | 0.070 |
Why?
| | Quality of Life | 1 | 2022 | 3211 | 0.070 |
Why?
| | Child | 3 | 2024 | 22740 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2181 | 0.060 |
Why?
| | Young Adult | 4 | 2020 | 14254 | 0.060 |
Why?
| | Ovomucin | 1 | 2026 | 9 | 0.060 |
Why?
| | Colorado | 3 | 2023 | 4556 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 12 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4151 | 0.060 |
Why?
| | Schools, Medical | 1 | 2026 | 159 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2026 | 268 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2024 | 2805 | 0.050 |
Why?
| | Kidney | 2 | 2025 | 1497 | 0.050 |
Why?
| | Autophagy-Related Proteins | 1 | 2022 | 46 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 177 | 0.040 |
Why?
| | World Health Organization | 1 | 2022 | 104 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 2022 | 85 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 37 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 172 | 0.040 |
Why?
| | Immunity | 1 | 2022 | 140 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 241 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 142 | 0.040 |
Why?
| | Respiratory Burst | 1 | 2020 | 19 | 0.040 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2020 | 32 | 0.040 |
Why?
| | Aminoglutethimide | 1 | 2020 | 4 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 265 | 0.040 |
Why?
| | Granulocytes | 1 | 2020 | 82 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8347 | 0.040 |
Why?
| | Drug Repositioning | 1 | 2020 | 39 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2020 | 115 | 0.040 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2020 | 90 | 0.040 |
Why?
| | Off-Label Use | 1 | 2020 | 51 | 0.040 |
Why?
| | Drug Resistance | 1 | 2020 | 145 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 119 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 291 | 0.040 |
Why?
| | Autoimmunity | 1 | 2025 | 933 | 0.040 |
Why?
| | Complement C4 | 1 | 2018 | 26 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2020 | 762 | 0.030 |
Why?
| | NF-kappa B | 1 | 2022 | 667 | 0.030 |
Why?
| | Furocoumarins | 1 | 2018 | 8 | 0.030 |
Why?
| | Phenylalanine | 1 | 2018 | 69 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5925 | 0.030 |
Why?
| | Transfection | 1 | 2020 | 927 | 0.030 |
Why?
| | Complement C3 | 1 | 2018 | 187 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1217 | 0.030 |
Why?
| | United States | 2 | 2026 | 16126 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2016 | 200 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1166 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 247 | 0.030 |
Why?
| | IgA Deficiency | 1 | 2015 | 5 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1898 | 0.030 |
Why?
| | Listeria monocytogenes | 1 | 2016 | 103 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 11794 | 0.030 |
Why?
| | Cholangitis | 1 | 2015 | 22 | 0.030 |
Why?
| | Hepatitis | 1 | 2015 | 43 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 128 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 97 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 2823 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2018 | 409 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2015 | 100 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2015 | 362 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2016 | 344 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 450 | 0.030 |
Why?
| | Thymus Gland | 1 | 2015 | 312 | 0.030 |
Why?
| | Exons | 1 | 2015 | 364 | 0.030 |
Why?
| | Fibrillins | 1 | 2013 | 9 | 0.020 |
Why?
| | Marfan Syndrome | 1 | 2013 | 46 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2013 | 135 | 0.020 |
Why?
| | Sinusitis | 1 | 2015 | 227 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 332 | 0.020 |
Why?
| | Occupational Exposure | 1 | 2015 | 355 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1139 | 0.020 |
Why?
| | Blood Glucose | 1 | 2020 | 2344 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 8078 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3130 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4568 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3634 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5992 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 6085 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10919 | 0.010 |
Why?
| | Mice | 1 | 2016 | 18355 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|